PDB71 - ASSESSING THE RELATIVE COST-EFFECTIVENESS OF EMPAGLIFLOZIN AND CANAGLIFLOZIN FOR THE TREATMENT OF TYPE 2 DIABETES PATIENTS WITH EXISTING CARDIOVASCULAR DISEASE IN THE UK

Authors :: Anuraag R. Kansal
S. Webster
Odette Reifsnider
Anastasia Ustyugova
N. Hau
Source :: Value in Health. 21:S130
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: Canagliflozin
medicine.medical_specialty
business.industry
Health Policy
Public Health, Environmental and Occupational Health
Type 2 diabetes
Disease
medicine.disease
Relative cost
medicine
Empagliflozin
business
Intensive care medicine
medicine.drug

Full Text Access

Tools